|
gptkbp:instanceOf
|
gptkb:antibiotic
glycylcycline
|
|
gptkbp:activeIn
|
Gram-negative bacteria
Gram-positive bacteria
anaerobic bacteria
|
|
gptkbp:approvalYear
|
2005
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
J01AA12
|
|
gptkbp:brand
|
gptkb:Tygacil
|
|
gptkbp:CASNumber
|
220620-09-7
|
|
gptkbp:chemicalFormula
|
C29H39N5O8
|
|
gptkbp:color
|
yellow to orange powder
|
|
gptkbp:contraindication
|
pregnancy
children under 8 years
hypersensitivity to tetracyclines
|
|
gptkbp:derivedFrom
|
gptkb:minocycline
|
|
gptkbp:developedBy
|
gptkb:Wyeth_Pharmaceuticals
|
|
gptkbp:eliminationHalfLife
|
27-43 hours
|
|
gptkbp:excretion
|
renal
biliary
|
|
gptkbp:firstBook
|
glycylcycline antibiotics
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
tigecycline
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits bacterial protein synthesis
|
|
gptkbp:metabolism
|
minimal
|
|
gptkbp:molecularWeight
|
585.65 g/mol
|
|
gptkbp:notEffectiveAgainst
|
gptkb:Pseudomonas_aeruginosa
gptkb:Proteus_species
gptkb:Providencia_species
urinary tract infections
bacteremia
|
|
gptkbp:origin
|
semisynthetic
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:proteinBinding
|
71-89%
|
|
gptkbp:resistantTo
|
efflux pumps
ribosomal protection proteins
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
increased mortality risk
|
|
gptkbp:solubility
|
water soluble
|
|
gptkbp:spectrumOfActivity
|
broad-spectrum
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:usedFor
|
gptkb:community-acquired_bacterial_pneumonia
complicated intra-abdominal infections
complicated skin and skin structure infections
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:vancomycin-resistant_Enterococcus_(VRE)
gptkb:Tygacil
gptkb:vancomycin-resistant_enterococci_(VRE)
|
|
gptkbp:bfsLayer
|
6
|